Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$1.60
-$0.04(-2.50%)
At close: 4:00 PM EDT
$1.60
-$0.04(-2.50%)
Day’s Range― - ―
52-Week Range$1.27 - $3.56
Previous Close$1.6
Volume150.11K
Average Volume (3M)421.23K
Market Cap
$79.28M
Enterprise Value-$13.37
Total Cash (Recent Filing)$89.96M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Nov 12, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding42,853,363
10 Day Avg. Volume442,643
30 Day Avg. Volume421,228
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.00Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Proprietary AP3 PlatformAcrivon's AP3 platform is a durable competitive asset: by identifying patient subsets most likely to respond, it can reduce clinical trial failure risk, sharpen go/no-go decisions, and improve partner and payer interest. Over months, this drives more efficient development and higher signal-to-noise in studies.
Focused Lead Program (WEE1)A focused lead candidate against the WEE1 pathway gives a clear clinical development trajectory. Combined with a biomarker-driven AP3 approach, this narrows trial populations, shortens paths to clear efficacy readouts, and supports targeted regulatory or partnership strategies that matter over a multi-month development horizon.
Low Financial LeverageVery low debt reduces bankruptcy and interest-rate sensitivity, preserving operational flexibility. For a cash-burning biotech, minimal leverage means fewer fixed obligations, enabling management to prioritize R&D or negotiate licensing without near-term pressure from creditors.
Bears Say
Pre-revenue And Heavy Cash BurnAcrivon is pre-revenue with large recurring losses and negative free cash flow, creating structural dependence on external financing. Over the next 2–6 months this elevates execution and dilution risk: clinical progress requires sustained funding, and financing terms can constrain strategic optionality.
Eroding Equity BaseMeaningful decline in shareholders' equity signals accumulated capital consumption and repeated losses. This shrinks the buffer against future write-downs, limits non-dilutive financing capacity, and increases likelihood that upcoming capital needs will be met via equity dilution or onerous deals.
Dilution Risk From Expanded Equity PlanApproval of a much larger equity incentive pool with automatic annual increases institutionalizes future dilution for compensation and hiring. Over the medium term, this raises share count uncertainty, pressures per-share economics, and signals reliance on stock-based pay to retain talent in a competitive biotech labor market.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.27 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $79.28M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 89 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.502 by $0.072.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.46.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 42,853,363 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.502. Following the earnings report the stock price went up 7.558%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (525.00% Upside)
$10.00 (525.00% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.51%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$10.00
▲(525.00% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
35.82% Insiders
2.57% Mutual Funds
34.99% Other Institutional Investors
24.12% Public Companies and
Individual Investors